Skip to main content

Table 1 Clinicopathological data of MMR-defective tumors

From: Low frequency of defective mismatch repair in a population-based series of upper urothelial carcinoma

Case no.

Sex / Age

Tumor location (Synchron./Metachron.)

WHO-Grade

Stage

Instable markers

Immunohistochemical expression

      

MLH1

MSH2

MSH6

PMS2

U1-113

F/54

ureter

G2

pTX

NE

+

-

-

+

 

53

endometrium (M)

  

4/6

+

-

-

+

U2-229

F/57

ureter

G2

pT1

4–5/6

-

+

+

-

 

57

ureter (S)

  

4–5/6

-

+

+

-

U3-821

M/61

ureter*

G2

pT1

2–3/6

+

-

-

+

RP1-101

M/60

renal pelvis

G2

pT3

3/5

+

-

-

+

 

43

sarcoma (M)

  

3/4

+

-

-

+

 

53

colon (M)

  

1/6¤

+

-

-

+

RP2-131

M/75

renal pelvis

G3

pT4

2/6

+

+

+

+

RP3-119

F/69

renal pelvis

G3

pTa

0/6

-

+

NE

-

RP4-267

F/67

renal pelvis

G2

pT1

5/5

+

-

-

+

 

70

urinary bladder (M)

  

3/4

+

-

-

+

RP5-401

M/56

renal pelvis

G2

pTa

0/6

+

+

-

+

RP6-528

F/87

renal pelvis

G2

pT1

2/5

+

+

+

+

 

87

urinary bladder (S)

  

0/6

+

+

+

+

RP7-613

F/57

renal pelvis^

G2

pT1

3/6

+

+

-

+

 

54

urinary bladder (M)

  

4/6

+

-

-

+

RP8-626

M/66

renal pelvis

G3

pT2

6/6

+

-

-

+

RP9-701

F/49

renal pelvis#

G2

pTa

0/5

+

-

NE

+

RP10-809

F/82

renal pelvis

G3

pT4

4/4

+

-

-

+

  1. ¤Positive for BAT26
  2. * Myelofibrosis at the age of 67 years.
  3. ^Cervical cancer at the age of 33.
  4. # Rectal tumor at the age of 38.
  5. G2 moderately differentiated
  6. G3 poorly differentiated